Soluble guanylate cyclase

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 6, 2000, Pages 735-749

  Hobbs, Adrian J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

angina pectoris; anti inflammatory; atherosclerosis; cGMP; glaucoma; haemoprotein; hypertension; impotence; migraine; nitric oxide; non adrenergic; non cholinergic; ODQ; restenosis; septic shock; soluble guanylate cyclase; YC 1

Indexed keywords

EID: 0000092376     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.6.735     Document Type: Review

References (142)

1. HARDMAN JG, SUTHERLAND EW: Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3′,5′-monophosphate from guanosine triphosphate. J. Biol. Chem. (1969) 244:6363-6370.
2. IGNARRO LJ, BUGA GM, WOOD KS, BYRNS RE, CHAUDHURI G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA (1987) 84:9265-9269.
3. PALMER RM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327:524-526.
4. FURCHGOTT RF: Studies on the relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is organic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Mechanisms of Vasodilation. Vanhoutte PM (Ed.), Raven Press, New York, USA (1988) 31-36.
5. HIBBS JB, JR., TAINTOR RR, VAVRIN Z, RACHLIN EM: Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. (1988) 157:87-94.
6. LEPOIVRE M, FIESCHI F, COVES J, THELANDER L, FONTECAVE M: Inactivation of ribonucleotide reductase by nitric oxide. Biochem. Biophys. Res. Commun. (1991) 179:442-448.
7. BROWN GC: Reversible binding and inhibition of catalase by nitric oxide. Eur. J. Biochem. (1995) 232:188-191.
8. LIZASOAIN I, MORO MA, KNOWLES RG, DARLEY-USMAR V, MONCADA S: Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem. J. (1996) 314(Pt 3):877-880.
9. BROWN GC: Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett. (1995) 369:136-139.
10. HOGGN: Biological chemistry and clinical potential of S-nitrosothiols. Free Radic. Biol. Med. (2000) 28:1478-1486.
11. RADI R, BECKMAN JS, BUSH KM, FREEMAN BA: Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. (1991) 288:481-487.
12. WOLIN MS, WOOD KS, IGNARRO LJ: Guanylate cyclase from bovine lung. A kinetic analysis of the regulation of the purified soluble enzyme by protoporphyrin IX, heme and nitrosyl-heme. J. Biol. Chem. (1982) 257:13312-13320.
13. LINCOLN TM, CORNWELL TL, KOMALAVILAS P, BOERTH N: Cyclic GMP-dependent protein kinase in nitric oxide signaling. Methods Enzymol. (1996) 269:149-166.
14. KAUPP UB: Family of cyclic nucleotide gated ion channels. Curr. Opin. Neurobiol. (1995) 5:434-442.
15. BEAVO JA, REIFSNYDER DH: Primary sequence ofcyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150-155.
16. KAMISAKI Y, SAHEKI S, NAKANE M et al.: Soluble guanylate cyclase from rat lung exists as a hetero-dimer. J. Biol. Chem. (1986) 261:7236-7241.
17. HUMBERT P, NIROOMAND F, FISCHER G et al.: Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. Eur. J. Biochem. (1990) 190:273-278.
18. HARTENECK C, WEDEL B, KOESLING D et al.: Molecular cloning and expression of a new alpha-subunit of soluble guanylyl cyclase. Interchangeability of the alpha-subunits of the enzyme. FEBS Lett. (1991) 292:217-222.
19. YUEN PS, POTTER LR, GARBERS DL: A new form of guanylyl cyclase is preferentially expressed in rat kidney. Biochemistry (1990) 29:10872-10878.
20. GIUILI G, SCHOLL U, BULLE F, GUELLAEN G: Molecular cloning of the cDNAs coding for the two subunits of soluble guanylyl cyclase from human brain. FEBS Lett. (1992) 304:83-88.
21. ZABEL U, WEEGER M, LA M, SCHMIDT HH: Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Biochem. J. (1998) 335(Pt 1):51-57.
22. BUDWORTH J, MEILLERAIS S, CHARLES I, POWELL K: Tissue distribution of the human soluble guanylate cyclases. Biochem. Biophys. Res. Commun. (1999) 263:696-701.
23. RITTER D, TAYLOR JF, HOFFMANN JW et al.: Alternative splicing for the alpha1 subunit of soluble guanylate cyclase. Biochem. J. (2000) 346(Pt 3):811-816.
24. RUSSWURM M, BEHRENDS S, HARTENECK C, KOESLING D: Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem. J. (1998) 335(Pt 1):125-130.
25. BEHRENDS S, HARTENECK C, SCHULTZ G, KOESLING D: A variant of the alpha 2 subunit of soluble guanylyl cyclase contains an insert homologous to a region within adenylyl cyclases and functions as a dominant negative protein. J. Biol. Chem. (1995) 270:21109-21113.
26. GUPTA G, AZAM M, YANG L, DANZIGER RS: The beta2 subunit inhibits stimulation of the alpha1/beta1 form of soluble guanylyl cyclase by nitric oxide. Potential relevance to regulation of blood pressure. J. Clin. Invest (1997) 100:1488-1492.
27. AZAM M, GUPTA G, CHEN W et al.: Genetic mapping of soluble guanylyl cyclase genes: implications for linkage to blood pressure in the Dahl rat. Hypertension (1998) 32:149-154.
28. CHEN L, DAUM G, FISCHER JW et al.: Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ. Res. (2000) 86:520-525.
29. BAUERSACHS J, BOULOUMIE A, MULSCH A et al.: Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression and in superoxide anion production. Cardiovasc. Res. (1998) 37:772-779.
30. KLOSS S, BOULOUMIE A, MULSCH A: Aging and chronic hypertension decrease expressionofrat aorticsoluble guanylyl cyclase. Hypertension (2000) 35:43-47.
31. RUETTEN H, ZABEL U,LINZ W, SCHMIDT HH:Downregu-lation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ. Res. (1999) 85:534-541.
32. HUSSAIN MB, HOBBS AJ, MACALLISTER RJ: Autoregula-tion of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta. Br. J. Pharmacol. (1999) 128:1082-1088.
33. IGNARRO LJ, DEGNAN JN, BARICOS WH, KADOWITZ PJ, WOLIN MS: Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim. Biophys. Acta (1982) 718:49-59.
34. WEDEL B, HUMBERT P, HARTENECK C et al.: Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc. Natl. Acad. Sci. USA (1994) 91:2592-2596.
35. FRIEBE A, WEDEL B, HARTENECK C et al.: Functions of conserved cysteines of soluble guanylyl cyclase. Biochemistry (1997) 36:1194-1198.
36. STONE JR, MARLETTA MA: Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry (1994) 33:5636-5640.
37. BURSTYN JN, YU AE, DIERKS EA, HAWKINS BK, DAWSON JH: Studies of the heme coordination and ligand binding properties of soluble guanylyl cyclase (sGC): characterization of Fe(II)sGC and Fe(II)sGC(CO) by electronic absorption and magnetic circular dichroism spectroscopies and failure of CO to activate the enzyme. Biochemistry (1995) 34:5896-5903.
38. BUECHLER WA, NAKANE M, MURAD F: Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem. Biophys. Res. Commun. (1991) 174:351-357.
39. HARTENECK C, KOESLING D, SOLING A, SCHULTZ G, BOHME E: Expression of soluble guanylyl cyclase. Catalytic activity requires two enzyme subunits. FEBS Lett. (1990) 272:221-223.
40. WILSON EM, CHINKERS M: Identification of sequences mediating guanylyl cyclase dimerization. Biochemistry (1995) 34:4696-4701.
41. STONE JR, SANDS RH, DUNHAM WR, MARLETTA MA: Spectral and ligand-binding properties of an unusual hemoprotein, the ferric form of soluble guanylate cyclase. Biochemistry (1996) 35:3258-3262.
42. DIERKS EA, BURSTYN JN: Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem. Pharmacol. (1996) 51:1593-1600.
43. OHLSTEIN EH, WOOD KS, IGNARRO LJ: Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effectsof heme and other factors on enzyme activation by NO, NO-heme and protopor-phyrin IX. Arch. Biochem. Biophys. (1982) 218:187-198.
44. MARKS GS, BRIEN JF, NAKATSU K, MCLAUGHLIN BE: Does carbon monoxide have aphysiological function? Trends Pharmacol. Sci. (1991) 12:185-188.
45. COCEANI F, KELSEY L, SEIDLITZ E et al.: Carbon monoxide formation in the ductus arteriosus in the lamb: implications for the regulation of muscle tone. Br. J. Pharmacol. (1997) 120:599-608.
46. LEINDERS-ZUFALL T, SHEPHERD GM, ZUFALL F: Regulation of cyclic nucleotide-gated channels and membrane excitability in olfactory receptor cells by carbon monoxide. J. Neurophysiol. (1995) 74:1498-1508.
47. CAUDILL TK, RESTA TC, KANAGY NL, WALKER BR: Role of endothelial carbon monoxide in attenuated vasore-activity following chronic hypoxia. Am. J. Physiol (1998) 275:R1025-R1030.
48. WERKSTROM V, NY L, PERSSON K, ANDERSSON KE: Carbon monoxide-induced relaxation and distribution of haem oxygenase isoenzymesin the pig urethra and lower oesophagogastric junction. Br. J. Pharmacol. (1997) 120:312-318.
49. MORLEY D, KEEFER LK: Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J. Cardiovasc. Pharmacol. (1993) 22(Suppl. 7):S3-S9.
50. SRINIVASAN A, SAAVEDRA JE, BONIFANT CL et al.: Targeting pharmacologic deliveryofnitric oxide (NO). Nitric Oxide (2000) 4:181-181.
51. KO FN, WU CC, KUO SC, LEE FY, TENG CM: YC-1, a novel activator of platelet guanylate cyclase. Blood (1994) 84:4226-4233.
52. WU CC, KO FN, KUO SC, LEE FY, TENG CM: YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. (1995) 116:1973-1978.
53. MULSCH A, BAUERSACHS J, SCHAFER A et al.: Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. (1997) 120:681-689.
54. FRIEBE A, KOESLING D: Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. (1998) 53:123-127.
55. LUO D, DAS S, VINCENT SR: Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur. J. Pharmacol. (1995) 290:247-251.
56. KUMAGAI Y, MIDORIKAWA K, NAKAI Y et al.: Inhibition of nitric oxide formation and superoxide generation during reduction of LY83583 by neuronal nitric oxide synthase. Eur. J. Pharmacol. (1998) 360:213-218.
57. KONTOS HA, WEI EP: Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke (1993) 24:427-434.
58. GIBSON A, MIRZAZADEH S: N-methylhydroxylamine inhibits and M&B 22948 potentiates relaxations of the mouse anococcygeus to non-adrenergic, non-cholinergic field stimulation and to nitrovasodi-lator drugs. Br. J. Pharmacol. (1989) 96:637-644.
59. GARTHWAITE J, SOUTHAM E, BOULTON CL et al.: Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one. Mol. Pharmacol. (1995) 48:184-188.
60. CELLEK S, KASAKOV L, MONCADA S: Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. Br. J. Pharmacol. (1996) 118:137-140.
61. MORO MA, RUSSEL RJ, CELLEK Set al.: cGMPmediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. USA (1996) 93:1480-1485.
62. WAYMAN CP, MCFADZEAN I, GIBSON A, TUCKER JF: Inhibition by sodium nitroprusside of a calcium store depletion-activated non-selective cation current in smooth muscle cells of the mouse anococcygeus. Br. J. Pharmacol. (1996) 118:2001-2008.
63. SCHRAMMEL A, BEHRENDS S, SCHMIDT K, KOESLING D, MAYER B: Characterization of 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. (1996) 50:1-5.
64. FEELISCH M, KOTSONIS P, SIEBE J, CLEMENT B, SCHMIDT HH: The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo [4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol. Pharmacol. (1999) 56:243-253.
65. MUNZEL T, KURZ S, HEITZER T, HARRISON DG: New insights into mechanisms underlying nitrate tolerance. Am. J. Cardiol. (1996) 77:24C-30C.
66. PARKER JD, PARKER JO: Nitrate therapy for stable angina pectoris. N. Engl. J. Med. (1998) 338:520-531.
67. ROTHERMUND L, FRIEBE A, PAUL M, KOESLING D, KREUTZ R: Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br. J. Pharmacol. (2000) 130:205-208.
68. COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration CooperativeStudy. N. Engl. J. Med. (1986) 314:1547-1552.
69. QIAN H, NEPLIOUEVA V, SHETTY GA, CHANNON KM, GEORGE SE: Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation (1999) 99:2979-2982.
70. PATEL RP, LEVONEN A, CRAWFORD JH, DARLEY-USMAR VM: Mechanisms of the pro-and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc. Res. (2000) 47:465-474.
71. MALEK AM, ALPER SL, IZUMO S: Hemodynamic shear stress and its role in atherosclerosis. JAMA (1999) 282:2035-2042.
72. BOHL KS, WEST JL: Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation [In Process Citation]. Biomaterials (2000) 21:2273-2278.
73. CHANNON KM, QIAN H, GEORGE SE: Nitric oxide synthase in atherosclerosis and vascular injury: insights from experimental gene therapy. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1873-1881.
74. SHEARS LL, KIBBE MR, MURDOCK AD et al.: Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J. Am. Coll. Surg. (1998) 187:295-306.
75. JANSSENS S, FLAHERTY D, NONG Z et al.: Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation (1998) 97:1274-1281.
76. VARENNE O, PISLARU S, GILLIJNS H et al.: Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation (1998) 98:919-926.
77. KUROSE I, KUBES P, WOLF R et al.: Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ. Res. (1993) 73:164-171.
78. CHICHE JD, SCHLUTSMEYER SM, BLOCH DB et al.: Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J. Biol. Chem. (1998) 273:34263-34271.
79. DUSTING GJ, FENNESSY P, YIN ZL, GUREVICH V: Nitric oxide in atherosclerosis: vascular protector or villain? Clin. Exp. Pharmacol. Physiol Suppl. (1998) 25:S34-S41.
80. LUSCHER TF, TANNER FC, DOHI Y: Age, hypertension and hypercholesterolaemia alter endothelium-dependent vascular regulation. Pharmacol. Toxicol. (1992) 70:S32-S39.
81. REES DD, CELLEK S, PALMER RM, MONCADA S: Dexamethasone prevents the induction by endotoxin ofa nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem. Biophys. Res. Commun. (1990) 173:541-547.
82. THIEMERMANN C, VANE J: Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur. J. Pharmacol. (1990) 182:591-595.
83. KILBOURN RG, GROSS SS, JUBRAN A et al.: NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA (1990) 87:3629-3632.
84. GOODE HF, HOWDLE PD, WALKER BE, WEBSTER NR: Nitric oxide synthase activity is increased in patients with sepsis syndrome. Clin. Sci. (1995) 88:131-133.
85. LASZLOF, WHITTLE BJ, EVANS SM, MONCADA S: Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs. Eur. J. Pharmacol. (1995) 283:47-53.
86. MACMICKING JD, NATHAN C, HOM G et al.: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell (1995) 81:641-650.
87. WU CC, CHEN SJ, SZABO C, THIEMERMANN C, VANE JR: Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br. J. Pharmacol. (1995) 114:1666-1672.
88. RUETTEN H, SOUTHAN GJ, ABATE A, THIEMERMANN C: Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br. J. Pharmacol. (1996) 118:261-270.
89. PETROS A, LAMB G, LEONE A et al.: Effects of a nitric oxide synthase inhibitor inhumans with septic shock. Cardiovasc. Res. (1994) 28:34-39.
90. PETROS A, BENNETT D, VALLANCE P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet (1991) 338:1557-1558.
91. GROVER R, ZACCARDELLI D, COLICE G et al.: An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88),inpatients withseptic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. (1999) 27:913-922.
92. HUSSEIN Z, BEERAHEE M, GROVER R et al.: Pharmacoki-netics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Clin. Pharmacol. Ther. (1999) 65:1-9.
93. NATHAN CF, HIBBS JB, JR.: Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. (1991) 3:65-70.
94. CLEMENTI E, BROWN GC, FEELISCH M, MONCADA S: Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. USA (1998) 95:7631-7636.
95. MONCADA S, PALMER RM, HIGGS EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. (1991) 43:109-142.
96. KILBOURN RG, FONSECA GA, TRISSEL LA, GRIFFITH OW: Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J. Sci. Am. (2000) 6(Suppl. 1):S21-S30.
97. KILBOURN RG, FONSECA GA, GRIFFITH OW et al.: NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med. (1995) 23:1018-1024.
98. CAUWELS A, VAN MOLLE W, JANSSEN B et al.: Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity (2000) 13:223-231.
99. LANDER HM, HAJJAR DP, HEMPSTEAD BL et al.: A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J. Biol. Chem. (1997) 272:4323-4326.
100. MATTHEWS JR, BOTTING CH, PANICO M, MORRIS HR, HAY RT: Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res. (1996) 24:2236-2242.
101. COLASANTI M, PERSICHINI T: Nitric oxide: an inhibitor of NF-kappaB/Rel system in glial cells. Brain Res. Bull. (2000) 52:155-161.
102. GHOSH S, MAY MJ, KOPP EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. (1998) 16:225-260.
103. GUDI T, HUVAR I, MEINECKE Met al.: Regulation of gene expression by cGMP-dependent protein kinase. Transactivation of the c-fos promoter. J. Biol. Chem. (1996) 271:4597-4600.
104. GUDI T, HONG GK, VAANDRAGER AB, LOHMANN SM, PILZ RB: Nitric oxide and cGMP regulate gene expression in neuronal and glial cells by activating Type II cGMP-dependent protein kinase. FASEB J. (1999) 13:2143-2152.
105. IDRISS SD, GUDI T, CASTEEL DE et al.: Nitric oxide regulation of gene transcription via soluble guanylate cyclase and Type I cGMP-dependent protein kinase. J. Biol. Chem. (1999) 274:9489-9493.
106. GONG JH, RENZ H, SPRENGER H, NAIN M, GEMSA D: Enhancement of tumor necrosis factor-alpha gene expression by low doses of prostaglandin E2 and cyclic GMP. Immunobiology (1990) 182:44-55.
107. TETSUKA T, DAPHNA-IKEN D, MILLER BW et al.: Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. J. Clin. Invest (1996) 97:2051-2056.
108. INOUE T, FUKUO K, NAKAHASHI T et al.: cGMP upregu-lates nitric oxide synthase expression in vascular smooth muscle cells. Hypertension (1995) 25:711-714.
109. RAVICHANDRAN LV, JOHNS RA: Up-regulation of endothelial nitric oxide synthase expression by cyclic guanosine 3′,5′-monophosphate. FEBS Lett. (1995) 374:295-298.
110. POLTE T, ABATE A, DENNERY PA, SCHRODER H: Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1209-1215.
111. KIEMER AK, VOLLMAR AM: Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J. Biol. Chem. (1998) 273:13444-13451.
112. KIEMER AK, VOLLMAR AM: Effects of different natriuretic peptides on nitric oxide synthesis in macrophages. Endocrinology (1997) 138:4282-4290.
113. BAEUERLE PA, HENKEL T: Function and activation of NF-kappa B in the immune system. Ann. Rev. Immunol. (1994) 12:141-179.
114. TSAO PS, BUITRAGO R, CHAN JR, COOKE JP: Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation (1996) 94:1682-1689.
115. ELLIOTT SN, MCKNIGHT W, CIRINO G, WALLACE JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats [see comments]. Gastroenterology (1995) 109:524-530.
116. WALLACE JL, REUTER B, CICALA C et al.: A diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol. (1994) 257:249-255.
117. RAND MJ: Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin. Exp. Pharmacol. Physiol (1992) 19:147-169.
118. TODA N, OKAMURA T: Nitroxidergic nerve: regulation of vascular tone and blood flow in the brain. J. Hypertens. (1996) 14:423-434.
119. MELMAN A, GINGELL JC: The epidemiology and pathophysiology of erectile dysfunction. J. Urol. (1999) 161:5-11.
120. CELLEK S, RODRIGO J, LOBOS E et al.: Selective nitrergic neurodegeneration in diabetes melli. Br. J. Pharmacol. (1999) 128:1804-1812.
121. CELLEK S, MONCADA S: Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc. Natl. Acad. Sci. USA (1997) 94:8226-8231.
122. GLOSSMANN H, PETRISCHOR G, BARTSCH G: Molecular mechanisms of the effects of sildenafil (Viagra). Exp. Gerontol. (1999) 34:305-318.
123. KLONER RA, ZUSMAN RM: Cardiovascular effects of sildenafil citrate and recommendations for its use. Am. J. Cardiol. (1999) 84:11N-17N.
124. GOLDSTEIN I, LUE TF, PADMA-NATHAN H et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. (1998) 338:1397-1404.
125. MARMOR MF, KESSLER R: Sildenafil (Viagra) and ophthalmology. Surv. Ophthalmol. (1999) 44:153-162.
126. OHSHIRO K, PURI P: Pathogenesis of infantile hypertrophic pyloric stenosis: recent progress. Pediatr. Surg. Int. (1998) 13:243-252.
127. TOMITA R, TANJOH K, FUJISAKI S, FUKUZAWA M: The role of nitric oxide (NO) in the human pyloric sphincter. Hepatogastroenterology (1999) 46:2999-3003.
128. HUANG PL, DAWSON TM, BREDT DS, SNYDER SH, FISHMAN MC: Targeted disruption of the neuronal nitric oxide synthase gene. Cell (1993) 75:1273-1286.
129. CHUNG E, CURTIS D, CHEN Get al.: Genetic evidence for the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric stenosis. Am. J. Hum. Genet. (1996) 58:363-370.
130. READ SJ, MANNING P, MCNEIL CJ, HUNTER AJ, PARSONS AA: Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms. Brain Res. (1999) 847:1-8.
131. SOUTHAM E, CHARLES SL, GARTHWAITE J: The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion. Br. J. Pharmacol. (1996) 119:527-532.
132. BOULTON CL, SOUTHAM E, GARTHWAITE J: Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience (1995) 69:699-703.
133. LEWIN MR, WALTERS ET: Cyclic GMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons. Nature Neurosci. (1999) 2:18-23.
134. HAEFLIGER IO, DETTMANN E, LIU R et al.: Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv. Ophthalmol. (1999) 43(Suppl. 1):S51-S58.
135. NEUFELD AH: Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv. Ophthalmol. (1999) 43(Suppl. 1):S129-S135.
136. KOSS MC: Functional role of nitric oxide in regulation of ocular blood flow. Eur. J. Pharmacol. (1999) 374:161-174.
137. KAMIKAWATOKO S, TOKORO T, ISHIDA A et al.: Nitric oxide relaxes bovine ciliary muscle contracted by carbachol through elevation of cyclic GMP. Exp. Eye Res. (1998) 66:1-7.
138. NATHANSON JA: Nitrovasodilators as a new class of ocular hypotensive agents. J. Pharmacol. Exp. Ther. (1992) 260:956-965.
139. NATHANSON JA: Direct application of a guanylate cyclase activator lowers intraocular pressure. Eur. J. Pharmacol. (1988) 147:155-156.
140. HESSEMER V, SCHMIDT KG: Influence of the vasodilator drug isosorbide dinitrate on ocular circulation. Arch. Ophthalmol. (1997) 115:324-327.
141. GRUNWALD JE, DUPONT J,DREYER EB: Effect ofchronic nitrate treatment on retinal vessel caliber in open-angle glaucoma. Am. J. Ophthalmol. (1997) 123:753-758.
142. NEUFELD AH, SAWADA A, BECKER B: Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA (1999) 96:9944-9948.